Lila Hope focuses on the representation of life sciences companies discovering, developing and marketing pharmaceutical, vaccine, medical device, diagnostic and digital health products. She counsels clients ranging from privately-held companies to Fortune 500 companies. Lila specializes in transactions involving complex intellectual property, business, operational and legal issues, including strategic partnerships, discovery and option deals, and complex asset purchases. In addition, she counsels clients' management, operational and legal teams on matters involving licensing, supply, distribution, clinical trials, research collaborations and vendor services. She is also regularly involved in the evaluation of a company's product rights and operational risks in connection with financing, public offering and M&A transactions, including over 20 initial public offerings.  In addition, she maintains an active practice in cross-border licensing transactions, including 16 transactions involving Asian biotechnology companies between 2015 and 2019.

Download full bio